Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PhotoCure ASAFRA:PHS +0.19%71 EV-to-EBITDA is 7.51 as of Jul. 14, 2026, which is 34% below its 10-year median of 11.40. GuruFocus rates FRA:PHS with a GF Score™ of 71/100 and a GF Value™ of €6.29 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 739 Drug Manufacturers companies, PhotoCure ASA ranks better than 74.15% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PhotoCure ASA's enterprise value is €117.92 Mil.
PhotoCure ASA's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €15.71 Mil. Therefore, PhotoCure ASA's EV-to-EBITDA for today is 7.51.
The historical rank and industry rank for PhotoCure ASA's EV-to-EBITDA or its related term are showing as below:
FRA:PHS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -511.5 Med: 11.4 Max: 534.75
Current: 7.6
During the past 13 years, the highest EV-to-EBITDA of PhotoCure ASA was 534.75. The lowest was -511.50. And the median was 11.40.
FRA:PHS's EV-to-EBITDA is ranked better than 74.15% of 739
companies
in the Drug Manufacturers industry
Industry Median: 12.98
vs FRA:PHS: 7.60
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
PhotoCure ASA (FRA:PHS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PhotoCure ASA's PE Ratio (TTM) for today is calculated as:
PhotoCure ASA's share price for today is €5.20.
PhotoCure ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.283.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for PhotoCure ASA's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PHS vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PhotoCure ASA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhotoCure ASA EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PhotoCure ASA's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PhotoCure ASA's EV-to-EBITDA falls into.
PhotoCure ASA's current Enterprise Value is €117.92 Mil.
PhotoCure ASA's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €15.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhotoCure ASA (FRA:PHS) has a EV-to-EBITDA of 7.51 as of Jul. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PhotoCure ASA. This is 34% below median its historical median of 11.40. According to the industry distribution chart, PhotoCure ASA ranks #191 out of 739 companies in the Drug Manufacturers industry, placing it in the top 25.8%.
Is PhotoCure ASA's EV-to-EBITDA too high?
PhotoCure ASA's current EV-to-EBITDA of 7.51 is 34% below median its 10-year median of 11.40. The Drug Manufacturers industry median EV-to-EBITDA is 12.98. PhotoCure ASA's value of 7.51 is 42.1% below this industry median. Based on the distribution chart, PhotoCure ASA ranks #191 out of 739 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PhotoCure ASA has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhotoCure ASA's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PhotoCure ASA ranks #191 out of 739 companies for EV-to-EBITDA. This puts PhotoCure ASA in the upper half of its industry. The industry median EV-to-EBITDA is 12.98. PhotoCure ASA's value of 7.51 is 42.1% below this benchmark. While the company's 10-year median is 11.40 vs. the industry median of 12.98, PhotoCure ASA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.98, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PhotoCure ASA's current EV-to-EBITDA of 7.51 is 42.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PhotoCure ASA. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PhotoCure ASA's current EV-to-EBITDA is 7.51, which is 34% below median its own 10-year median of 11.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhotoCure ASA stock overvalued right now?
Based on GuruFocus' analysis, PhotoCure ASA (FRA:PHS) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.29, compared to a current price of €5.20 — trading 17.3% below its estimated fair value. The current EV-to-EBITDA is 7.51, which is 34% below median its 10-year median of 11.40 and 42.1% below the Drug Manufacturers industry median of 12.98. PhotoCure ASA's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PhotoCure ASA (FRA:PHS), the current EV-to-EBITDA is 7.51 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhotoCure ASA (FRA:PHS) Overvalued in 2026?
Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued.
The current stock price of €5.20 is trading 17.3% below its estimated GF Value™ of €6.29.
GuruFocus considers PhotoCure ASA to be Modestly Undervalued.
Key valuation signals for FRA:PHS:
EV-to-EBITDA: 7.51 (34% below median its 10-year median of 11.40)
GF Value™: €6.29 vs. price of €5.20 (17.3% below fair value)
Industry Position: 42.1% below the Drug Manufacturers median (#191 of 739)
No single metric tells the full story. See the FRA:PHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
71GF Score
Get the complete analysis for FRA:PHS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PHS has been successfully added to your 
